



# Improving Diagnostic Yield of Pancreatic Serous Cystadenoma with Cyst Fluid Ancillary Testing, Adjunct Immunohistochemistry, and Additional Fine Needle Biopsy Sampling

Xi Wang<sup>1</sup>, Xuchen Zhang<sup>1</sup>, Pei Hui<sup>1</sup>, Guoping Cai<sup>1,2</sup>

<sup>1</sup> Department of Pathology, Yale University School of Medicine, New Haven, CT

Xi Wang, MD/PhD, PGY-4 Connecticut Society of Pathologists Education Meeting Feb 24<sup>th</sup> 2024


Yale school of medicine

<sup>&</sup>lt;sup>2</sup> Yale Cancer Center, Yale University School of Medicine, New Haven, CT

### Serous Cystadenoma (SCA) of the Pancreas

- Benign non-mucinous neoplasm representing 10-16% of pancreatic cystic lesions.
- Ultrasound-guided fine-needle aspiration (EUS-FNA)
  has been increasingly used for the diagnosis
  preoperatively
- Histologically composed of multiple cysts lined by bland cuboidal epithelium.






Yale school of medicine


WHO Classification of Digestive System Tumours. 5th ed.

### The cytologic diagnosis of SCA has been challenging



- The specimen is usually paucicellular
- The aspirate is often bloody
- Reported diagnostic sensitivity ranges
   from 0-20%

#### One of the major changes in WHO involves SCA



Yale school of medicine

Nikas IP, et al. Int J Mol Sci. 2022 Jan 31;23(3):1650. PMID: 35163571.

### Aims of the study


- 1) How confident cytopathologists are in rendering a diagnosis of SCA with or without cyst fluid ancillary testing?
- 2) Could adjunct immunostaining help improve the diagnosis?
- 3) Is there an additive value of concurrent fine needle biopsy (FNB) sampling for the diagnosis of SCA?

#### **Case selection**

- ✓ We retrospectively searched for <u>histologically proved serous</u> cystadenoma cases which had been FNA sampled between May 2004 to May 2022.
- ✓ A total of 31 cases with SCA diagnosis confirmed on either concurrent fine needle biopsy (FNB) (N=11) or surgical resection (N=20) were identified.

| Age, year                        |           |
|----------------------------------|-----------|
| Mean                             | 65        |
| Range                            | 30-80     |
| Gender, n (%)                    |           |
| Male                             | 13 (42%)  |
| Female                           | 18 (58%)  |
| Tumor location, n (n%)           |           |
| Head/neck/uncinate               | 12 (39%)  |
| Body/tail                        | 19 (61%)  |
| Tumor size, cm                   |           |
| Mean                             | 4.8       |
| Range                            | 1.5-13    |
| Imaging findings, n (%)          |           |
| Cystic mass                      | 23 (74%)  |
| Solid mass                       | 6 (19%)   |
| Unknown                          | 2 (6%)    |
| Cytologic diagnosis, n (%)       |           |
| Serous cystadenoma               | 2 (6%)    |
| Suggestive of serous cystadenoma | 2 (6%)    |
| Non-mucinous cyst                | 11 (35%)  |
| Atypical cells                   | 3 (10%)   |
| Cyst contents                    | 6 (19%)   |
| Negative for malignancy          | 1 (3%)    |
| Nondiagnostic                    | 6 (19%)   |
| CEA level, n (%)                 |           |
| ≥ 192 ng/ml                      | 0         |
| < 192 ng/ml                      | 17 (100%) |
| Amylase level, n (%)             |           |
| ≥ 250 U/L                        | 3 (18%)   |
| < 250 U/L                        | 14 (82%)  |
| KRAS mutation                    |           |
| Mutant                           | 0         |
| Wild-type                        | 14 (100%) |


### Clinical features, cytologic diagnosis, and cyst fluid ancillary tests of pancreatic SCA




### Aims of the study

- 1) How confident cytopathologists are in rendering a diagnosis of SCA with or without cyst fluid ancillary testing?
- 2) Could adjunct immunostaining help improve the diagnosis?
- 3) Is there an additive value of concurrent fine needle biopsy (FNB) sampling for the diagnosis of SCA?

### **Expression of inhibin, CA-IX and Glut-1 in SCAs**




### Expression of inhibin, CA-IX and Glut-1 in normal gastric and duodenal epithelium



Yale school of medicine

### **Expression of inhibin in FNA cell blocks**



Yale school of medicine

### The diagnostic yield was improved in 5 out of 7 cases

| Case | Original Diagnosis     | Cyst Fluid Ancillary Test           | Immunohistochemistry |  |
|------|------------------------|-------------------------------------|----------------------|--|
| 1    | Consistent with serous | No cyst fluid analysis              | Inhibin +            |  |
|      | cystadenoma            | Scant cellularity                   |                      |  |
| 2    | Non-mucinous cyst      | No cyst fluid analysis              | Inhibin +            |  |
|      |                        | Scant cellularity                   |                      |  |
| 3    | Non-mucinous cyst      | WT KRAS                             | Inhibin +            |  |
|      |                        | Scant cellularity                   |                      |  |
| 4    | Non-mucinous cyst      | CEA 26 ng/ml, amylase 5288, WT KRAS | Inhibin +            |  |
|      |                        | Scant cellularity                   |                      |  |
| 5    | Non-mucinous cyst      | No cyst fluid analysis              | Inhibin +            |  |
|      |                        | Scant cellularity                   |                      |  |
| 6    | Cyst contents          | CEA 1.1 ng/ml, amylase 20 U/L       | Inhibin +/-          |  |
|      |                        | Scant cellularity                   |                      |  |
| 7    | Nondiagnostic          | No cyst fluid analysis              | Inhibin +            |  |
|      |                        | Scant cellularity                   |                      |  |

### Aims of the study

- 1) How confident cytopathologists are in rendering a diagnosis of SCA with or without cyst fluid ancillary testing?
- 2) Could adjunct immunostaining help improve the diagnosis?
- 3) Is there an additive value of concurrent fine needle biopsy (FNB) sampling for the diagnosis of SCA?

## Concurrent FNA and FNB diagnosis for SCAs

| _    | T              |                                   | I             |                        |
|------|----------------|-----------------------------------|---------------|------------------------|
| Case | FNA Diagnosis  | Ancillary Testing                 | FNB Diagnosis | Ancillary Testing      |
| 1    | Cyst contents  | WT KRAS                           | SCA           | AE1/AE3+, inhibin+,    |
|      |                | Acellular block                   |               | chromogranin-          |
| 2    | Non-mucinous   | CEA 0.2 ng/ml; amylase 181        | S/O SCA       | CK7+, CK19+, inhibin+, |
|      | cyst           | U/L; WT <i>KRAS</i>               |               | PAS+                   |
|      |                | Acellular block                   |               |                        |
| 3    | Non-mucinous   | CEA 30 ng/ml; amylase 7854        | LG neoplasm   | AE1/AE3+, Inhibin+,    |
|      | cyst           | U/L; WT <i>KRAS</i>               |               | PAX8+,                 |
|      |                | No cell block                     |               | Synaptophysin+,        |
|      |                |                                   |               | chromogranin+          |
| 4    | Non-mucinous   | CEA 26 ng/ml; amylase 5288        | SCA           | Inhibin+, CA-IX+,      |
|      | cyst           | U/L; WT <i>KRAS</i>               |               | Synaptophysin-, PAX8-  |
|      |                | Scant cellularity                 |               |                        |
| 5    | S/O SCA        | CEA 17 ng/ml; amylase 13 U/L;     | S/O SCA       | Inhibin+               |
|      |                | WT KRAS                           |               |                        |
|      |                | Scant cellularity                 |               |                        |
| 6    | Non-mucinous   | CEA 15 ng/ml; amylase 76 U/L;     | S/O SCA       | Inhibin+, PAS+         |
|      | cyst           | WT KRAS                           |               |                        |
|      |                | No cell block                     |               |                        |
| 7    | Non-mucinous   | No cyst fluid analysis            | S/O SCA       | AE1/AE3+, Inhibin+,    |
|      | cyst           | No cell block                     |               | Synaptophysin-, PAS+   |
| 8    | Non-mucinous   | CEA 154 ng/ml; amylase 483        | S/O SCA       | CK7+, CK19+, inhibin+, |
|      | cyst           | U/L; WT <i>KRAS</i>               |               | PAS+                   |
|      |                | No cell block                     |               |                        |
| 9    | Nondiagnostic  | No cyst fluid analysis            | Nondiagnostic | Inhibin-,              |
|      |                | No cell block                     |               | Synaptophysin-         |
| 10   | Nondiagnostic  | No cyst fluid analysis            | SCA           | AE1/AE3+, CK7+,        |
|      |                | No cell block                     |               | Inhibin+, CEA-         |
| 11   | Atypical cells | No cyst fluid analysis            | SCA           | N/A                    |
|      |                | No cell block                     |               |                        |
| 12   | Non-mucinous   | No cyst fluid analysis            | SCA           | CK7+, PAS+             |
|      | cyst           | Low cellularity                   |               |                        |
| 13   | Non-mucinous   | No cyst fluid analysis            | S/O SCA       | N/A                    |
|      | cyst           | No cell block                     |               |                        |
| 14   | Non-mucinous   | No cyst fluid analysis            | SCA           | AE1/AE3+, inhibin+     |
|      | cyst           | Scant cellularity; inhibin, Glut- |               |                        |
|      |                | 1 noncontributory                 |               |                        |
| 15   | Cyst contents  | No cyst fluid analysis            | SCA           | AE1/AE3+, inhibin+,    |
|      |                | Scant cellularity; inhibin        |               | Synaptophysin-,        |
|      |                | noncontributory                   |               | INSM1-                 |
|      |                |                                   |               |                        |

#### **Conclusions**

- Diagnosing SCA based on aspiration cytology alone is very difficult.
- There is an important role of cystic fluid ancillary testing.
- Inhibin is one of the best markers for cytologic materials.
- Most importantly, additional sampling with FNB will provide additive diagnostic value.

This manuscript has been accepted by Cancer Cytopathology.

### **Acknowledgement**

Dr. Guoping Cai

Dr. Xuchen Zhang

Dr. Pei Hui

### Thank you!

**Supplemental Table 1.** Clinicopathologic features and ancillary tests of pancreatic serous cystadenoma diagnosed on FNA without surgical resection.

| Case | Age, | Gender | Location  | Imaging                          | FNA       | Immunostain                    | CEA,  | Amylase, | KRAS     |
|------|------|--------|-----------|----------------------------------|-----------|--------------------------------|-------|----------|----------|
|      | year |        |           | findings                         | diagnosis |                                | ng/ml | U/L      | mutation |
| 1    | 73   | F      | Body/Tail | Cystic lesion                    | SCA       | Non-<br>contributory           | 0.7   | 83       | N/A      |
| 2    | 63   | F      | Head      | Cystic lesion                    | S/O SCA   | CD56+,<br>SYN-, CHR-,<br>PAS+  | N/A   | N/A      | WT       |
| 3    | 77   | F      | Head      | Large<br>microcystic,<br>S/O SCA | SCA       | N/A                            | N/A   | N/A      | WT       |
| 4    | 72   | M      | Head      | Cystic lesion                    | S/O SCA   | N/A                            | 0.2   | 52       | WT       |
| 5    | 44   | M      | Body      | Cystic lesion                    | S/O SCA   | N/A                            | 0.3   | 1441     | WT       |
| 6    | 63   | F      | Body      | Cystic lesion                    | SCA       | N/A                            | 0.2   | 16.2     | N/A      |
| 7    | 54   | F      | Head      | Cystic<br>lesion, S/O<br>SCA     | S/O SCA   | N/A                            | N/A   | N/A      | N/A      |
| 8    | 49   | F      | Tail      | Cystic<br>lesion, S/O<br>SCA     | S/O SCA   | N/A                            | 0.2   | 27       | N/A      |
| 9    | 79   | M      | Head      | Cystic lesion                    | S/O SCA   | N/A                            | N/A   | N/A      | N/A      |
| 10   | 82   | F      | Head      | Cystic<br>lesion, S/O<br>SCA     | S/O SCA   | N/A                            | 0.5   | 47       | N/A      |
| 11   | 63   | M      | Uncinate  | Cystic lesion                    | S/O SCA   | Inhibin+,<br>CA-IX+,<br>Glut1+ | 0.2   | 219      | WT       |
| 12   | 67   | F      | Tail      | Cystic lesion                    | S/O SCA   | Inhibin+ on thin prep          | 0.2   | 21       | WT       |

Yale school of Medicine

**Supplemental Table 2.** Rapid on-site evaluation interpretation and follow-up of selective serous cystadenoma cases.

| Case # | ROSE interpretation                        | Additional aspirate | Cell block                 | Immunostain                   | Final FNA diagnosis |
|--------|--|---------------------|----------------------------|-------------------------------|---------------------|
| 1      | Pancreatic acinar cells                    | Yes                 | Acellular                  | N/A                           | Cyst contents       |
| 2      | Rare inflammatory cells, paucicellular     | No                  | Acellular                  | N/A                           | Non-mucinous        |
| 3      | Mild atypical epithelium                   | Yes                 | Hemosiderin<br>histiocytes | N/A                           | Non-mucinous        |
| 4      | Predominantly blood and GI contaminant     | Yes                 | No                         | N/A                           | Non-mucinous        |
| 5      | Few cells                                  | Yes                 | Acellular                  | N/A                           | Nondiagnostic       |
| 6      | Blood, few cells                           | Yes                 | No                         | N/A                           | Nondiagnostic       |
| 7      | Bland ductal epithelial cells, macrophages | Yes                 | Hemosiderin<br>histiocytes | N/A                           | Serous cyst         |
| 8      | Amorphous debris                           | Yes                 | No                         | N/A                           | Non-mucinous        |
| 9      | Bland cuboidal cells, cannot exclude SCA   | Yes                 | Low cellularity            | Inhibin, Glut-1<br>suboptimal | Non-mucinous        |
| 10     | Nondiagnostic                              | Yes                 | Acellular                  | N/A                           | Atypical            |

ROSE: Rapid on-site evaluation; SCA: serous cystadenoma; N/A, not performed.